1 Result(s)

Article

Burden of tumor mutations, neoepitopes, and other variants are weak predictors of cancer immunotherapy response and overall survival

Tumor mutational burden (TMB; the quantity of aberrant nucleotide sequences a given tumor may harbor) has been associated with response to immune checkpoint inhibitor therapy and is gaining broad acceptance as...

Mary A. Wood, Benjamin R. Weeder, Julianne K. David, Abhinav Nellore… in Genome Medicine (2020)